Skip to main content

Metformin

01-12-2023 | Older adults | News

Lower glucose may slow ageing in type 2 diabetes

People with type 2 diabetes who maintain low glycated haemoglobin levels have slower progression of frailty over time than those with higher levels, shows an analysis of Look AHEAD participants.

12-20-2022 | Metformin | News

Metformin linked to reduced risk for joint replacement

Metformin use is associated with a significant reduction in the risk for total knee or hip replacement among people with type 2 diabetes, shows research published in CMAJ.

10-14-2022 | Dementia | News

Glitazone use linked to reduced dementia risk in type 2 diabetes

People aged 60 years or older receiving thiazolidinedione monotherapy for type 2 diabetes may have a lower risk for dementia than those taking metformin monotherapy, an observational study suggests.

Piggy bank balancing on seesaw over a bottle of pills

10-04-2022 | Healthcare costs | News

First-line SGLT2 inhibitors, GLP-1 receptor agonists ‘not cost effective’

The authors of a modeling study say that the price of SGLT2 inhibitors and GLP-1 receptor agonists would need to fall “by at least 70%” for them to be cost effective as first-line treatments in the USA.

Doctor holds in his hands the kidney concept

09-01-2022 | Metformin | News

People with type 2 diabetes and CKD missing out on renoprotective drugs

People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.

06-05-2022 | ADA 2022 | Conference coverage | News

Vitamin B12 monitoring rare despite metformin prescription

Clinicians are only rarely monitoring vitamin B12 levels in people with type 2 diabetes using metformin, research shows.

06-01-2022 | Cardiovascular outcomes | News

No long-term CV benefits seen 2 decades after DPP interventions

People with impaired glucose tolerance who received metformin or intensive lifestyle intervention during the DPP trial show no sign of a significantly reduced cardiovascular disease risk 21 years later, reveal the latest DPPOS results.

05-27-2022 | SGLT2 inhibitors | News

Heart failure benefits seen with first-line SGLT2 inhibition

People who start SGLT2 inhibitors as a first-line diabetes treatment have a reduced risk for heart failure hospitalization relative to those who start metformin and a similar risk for other vascular outcomes, a study shows.